Angle Plc (AGL.L) Announced that a leading customer has established a multi-centre study to investigate biomarkers on
circulating tumor cells (CTCs), using the company's Parsortix system, which may give advance
warning of relapse in non-small cell lung cancer (NSCLC). The study is being conducted by the
Hellenic Oncology Research Group (Hellenic) lead by the Principal Investigators, Associate Professor
Athanasios Kotsakis and Professor Vassilis Georgoulias of the IASO General Hospital in Athens,
Greece and is investigating both ctDNA (circulating tumor DNA, fragments of dead cancer cells) and
CTCs. The CTC evaluation is being undertaken by the University of Athens lead by Professor Evi
Lianidou. Parsortix is the only CTC system being used in the study.